Psilocybin for the Treatment of Obsessive-Compulsive Disorders
- 17 November 2021
- book chapter
- Published by Springer Nature
- Vol. 56, 247-259
Abstract
Obsessive-compulsive disorder (OCD) is a highly prevalent and disabling condition for which currently available treatments are insufficiently effective and alternatives merit priority attention. Psilocybin may represent a safe and effective avenue for treatment of individuals affected by this condition. In this chapter we briefly introduce OCD symptoms, epidemiology, as well as relevant hypotheses on the mechanism of disease that may inform treatment interventions. We briefly describe currently available treatments, mechanisms of action, and efficacy limitations, as preamble to the potential use of psilocybin and perhaps similar compounds in the treatment of OCD and related conditions. Although much is reviewed throughout this book about the mechanisms of action of psychedelic agents, a focused discussion of psilocybin effects as they pertain to OCD is also included. Our experience with incidental observation, prospective research, and current explorations of psilocybin in OCD are also described.Keywords
This publication has 30 references indexed in Scilit:
- Psilocybin and Obsessive Compulsive DisorderJournal of Psychoactive Drugs, 2014
- Differential contributions of worry, anxiety, and obsessive compulsive symptoms to ERN amplitudes in response monitoring and reinforcement learning tasksNeuropsychologia, 2014
- The default network and self‐generated thought: component processes, dynamic control, and clinical relevanceAnnals of the New York Academy of Sciences, 2014
- Resting-State Functional Connectivity between Fronto-Parietal and Default Mode Networks in Obsessive-Compulsive DisorderPLOS ONE, 2012
- Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatmentPharmacology & Therapeutics, 2011
- Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonistsNeuroscience Letters, 2011
- Bupropion for Patients With Obsessive-Compulsive DisorderThe Journal of Clinical Psychiatry, 2005
- HallucinogensPharmacology & Therapeutics, 2004
- Hallucinogens, Serotonin and Obsessive-Compulsive DisorderJournal of Psychoactive Drugs, 1998
- Continuous exposure and complete response prevention in the treatment of obsessive-compulsive neurosisBehavior Therapy, 1978